Search All Jobs

Showing 8 of 8 Jobs

Coordinator - Hope Lodge

$16.50/hr

Coralville, IA, USA

Night Lead

$26.73/hr

Minneapolis, MN, USA

Guest Relations Manager - Hope Lodge

St. Louis, MO, USA

Night Lead - Hope Lodge

$25.46/hr

Rochester, MN, USA

Night Lead

$25.46/hr

Coralville, IA, USA

Night Lead - Hope Lodge

$25.46/hr

Rochester, MN, USA

Night Lead - Hope Lodge

$25.46/hr

Kansas City, MO, USA

Night Lead - Hope Lodge

$25.46/hr

Kansas City, MO, USA

Full-Time

Coordinator

Hope Lodge

Posted on 5/14/2025

American Cancer Society

American Cancer Society

5,001-10,000 employees

Advocacy, research, and patient support for cancer

Compensation Overview

$16.50/hr

+ Shift Differential Pay

Junior

Coralville, IA, USA

Category
Customer Experience & Support
Customer Experience
Customer Support
Required Skills
Salesforce
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a American Cancer Society referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • High School Diploma, GED or equivalent required.
  • Post-secondary education preferred.
  • At least one-year experience in healthcare, social services, hospitality services, or volunteer management, or an equivalent combination of experience and education preferred.
  • Receiving the COVID-19 vaccination is an essential function of this position and is necessary to ensure the health and safety of our guests who are undergoing cancer treatment.
  • Hope Lodge employees are expected to remain up-to-date with all adult vaccinations as recommended by the Centers for Disease Control and Prevention (CDC).
  • Excellent communication, customer service, analytic, computer, consulting skills and conflict resolution.
  • Ability to work independently and with minimum direction. Remains calm even under highly stressful situations.
  • A valid driver's license and clean driving record is required.
Responsibilities
  • Maintains the safety and comfort of Hope Lodge guests, volunteers, and other visitors as a primary focus and ensures any issues or concerns are addressed immediately and within policy.
  • Performs all guest interactions and processes including referrals, screening, check-in, orientation, stay, and check-out in strict adherence to Hope Lodge Operations policies.
  • Ensures timely and accurate reporting including ensuring data is entered into applicable software and systems (HMS, Salesforce, Marketplace, Concur, ADP, etc.).
  • Ensures timely completion of all required American Cancer Society trainings and compliance courses and attends all required staff meetings.
  • Performs any and all necessary responsibilities in the absence of additional staff or volunteers, including guest transportation, and ensures Hope Lodge is staffed at all times 24/7/365; fulfilling this responsibility may require unplanned/unscheduled time at the Lodge.
  • Assists in the recruitment, training, retention and utilization of volunteers in an appropriate manner to support Hope Lodge program delivery.
  • Serves as a spokesperson for the Hope Lodge and actively promotes community relations and awareness of Hope Lodge activities including tours for civic, community and health care groups.
  • Identifies development opportunities with Hope Lodge guests and community leaders that interact with Hope Lodge; assists with solicitation when appropriate.
  • Reviews and updates patient information, current lodge status, and maintenance logs at the beginning and end of each shift.
  • May provide rides for Hope Lodge guests to/from treatment centers and other destinations authorized by lodge management utilizing Hope Lodge vehicle in a safe, efficient and professional manner.
  • Tracks all rides provided, miles driven, safety issues and vehicle maintenance needed or completed.
  • Duties for a specific shift or lodge location may also include: 1.Cleaning/sanitizing common areas and/or guest rooms; 2.Working on laundry as assigned which may include washing, drying, folding, putting sheets and linens away and/or preparing rooms for incoming guests. Performs other duties as assigned.
Desired Qualifications
  • Post-secondary education preferred.
  • Experience in hospitality housing or similar residential management preferred.
American Cancer Society

American Cancer Society

View

The American Cancer Society focuses on fighting cancer through various means, including advocacy, research, and patient support. Their efforts aim to improve the lives of individuals affected by cancer and their families by providing resources and assistance for prevention, detection, treatment, and survivorship. Unlike other organizations, the American Cancer Society uniquely combines these elements to create a comprehensive approach to cancer care. Their goal is to end cancer as we know it, ensuring that everyone has access to the necessary tools and support to combat this disease.

Company Size

5,001-10,000

Company Stage

Series B

Total Funding

$2.7M

Headquarters

Atlanta, Georgia

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Besitos targets younger, tech-savvy audience for fundraising.
  • Multi-cancer early detection testing could lead to more funding for early initiatives.
  • Transportation grant improves patient adherence and outcomes in cancer treatment.

What critics are saying

  • Mobile gaming partnership may struggle to engage users effectively.
  • Transportation grant may not meet all patient needs, limiting program impact.
  • Focus on early detection may divert attention from traditional cancer research.

What makes American Cancer Society unique

  • American Cancer Society partners with Besitos for innovative mobile gaming fundraising.
  • Focus on multi-cancer early detection testing with GRAIL and Kate Walsh advocacy.
  • Grant to Cheyenne Regional Medical Center for patient transportation during cancer treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Paid Vacation

401(k) Retirement Plan

Wellness Program

Professional Development Budget

Company News

Forbes
May 13th, 2025
Tv Star Kate Walsh Talks About Multi-Cancer Early Detection Testing

Grey’s Anatomy star Kate Walsh discussed her parents experiences with cancer and her own cancer. More scare and the importance of detecting cancer early. (Photo: Courtesy of HelloMMC) Courtesy of HelloMMCGrey’s Anatomy star Kate Walsh called this decision a “no brainer” in both a serious and punny way. It’s her decision to team up with the company GRAIL to advocate for more multi-cancer early detection testing in a campaign they’re calling “Generation Possible.”What Is Multi-cancer Early Detection (MCED) Testing?Now MCED, short for multi-cancer early detection, isn’t exactly a term that’s already bandied about regularly like “OMG” or “IYKYK.” It’s a newer term that may at first sound quite technical. But breaking the term down to its component parts can help understand what it is. “Cancer" along with “early detection” means trying to catch cancer in its early stages before it’s spread and becomes much more difficult to treat

Cision
May 9th, 2025
Imfinzi Improved Dfs In Early Bladder Cancer

Imfinzi improved DFS in early bladder cancer

Cheyenne Regional Medical Center
May 6th, 2025
The American Cancer Society Awards 5K to The Cheyenne Regional Medical Center Foundation to Provide Transportation to Patients During Cancer Treatment

May 1, 2025 - The American Cancer Society has awarded a grant of $5,000 to the Cheyenne Regional Medical Center (CRMC) Foundation to provide transportation assistance for cancer patients undergoing treatment.

PharmiWeb
Apr 30th, 2025
Fixed-Duration Calquence-Based Regimens Recommended For Approval In The Eu By Chmp For 1St-Line Chronic Lymphocytic Leukaemia

Recommendation based on AMPLIFY Phase III trial which showed Calquencecombinations demonstrated statistically significant and clinically meaningfulimprovement in progression-free survival vs. chemoimmunotherapyA fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the AMPLIFY Phase III trial, which were presented at the American Society of Haematology (ASH) 2024 Annual Meeting and published in The New England Journal of Medicine.1Results showed Calquence plus venetoclax reduced the risk of disease progression or death by 35% compared to standard-of-care chemoimmunotherapy (investigator’s choice of fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab; hazard ratio [HR] 0.65; 95% confidence interval [CI] 0.49-0.87; p=0.0038). Calquence plus venetoclax with obinutuzumab demonstrated a 58% reduction in the risk of disease progression or death compared to standard-of-care chemoimmunotherapy (HR 0.42; 95% CI 0.30-0.59; p<0.0001).2At three years, 77% of patients treated with Calquence plus venetoclax and 83% of patients treated with Calquence plus venetoclax and obinutuzumab were progression free, versus 67% of patients treated with chemoimmunotherapy.1 Median progression-free survival (PFS) was not reached for either experimental arm versus 47.6 months for chemoimmunotherapy.1Wojciech Jurczak, MD, Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland and investigator for the trial, said: “Chronic lymphocytic leukaemia is an incurable cancer which means patients live with the disease and stay on treatment for many years, which can have long-term effects. The fixed-duration Calquence regimens will allow patients to take breaks from their treatment, reducing the risk of long-term adverse events and drug resistance.”Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “With this recommendation, Calquence plus venetoclax can potentially be the only all-oral second-generation BTK inhibitor option approved in Europe for patients with previously untreated chronic lymphocytic leukaemia. Calquence has demonstrated efficacy and safety in fixed-duration and treat-to-progression regimens providing patients and their doctors more treatment flexibility.”CLL is the most common type of leukaemia in adults, with an estimated 27,000 patients diagnosed in the UK, France, Germany, Spain and Italy in 2024.3The safety and tolerability of Calquence was consistent with its known safety profile, and no new safety signals were identified.Regulatory applications for Calquence plus venetoclax, with or without obinutuzumab, in this setting are currently under review in several countries based on the AMPLIFY results.NotesChronic lymphocytic leukaemia (CLL)CLL is the most prevalent type of leukaemia in adults, with over 117,000 new cases globally in 2021.4 Although some people with CLL may not experience any symptoms at diagnosis, others may experience symptoms, such as weakness, fatigue, weight loss, chills, fever, night sweats, swollen lymph nodes and abdominal pain.5 In CLL, there is an accumulation of abnormal lymphocytes within the blood, bone marrow and lymph nodes. As the number of abnormal cells increases, there is less room within the marrow for the production of normal white blood cells, red blood cells and platelets.6 This could result in infection, anaemia and bleeding

PR Newswire
Apr 29th, 2025
Bladder Cancer Presentations At Aua2025: Blue Light Cystoscopy Improves Risk Stratification And Informed Decision Making

OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management of the disease, improved risk stratification and therefore the ability of the BLC procedure to help urologists and patients make well-informed decisions. The American Urological Association Annual Congress 2025 was held April 26-28, at the Venetian Convention & Expo Center in Las Vegas, NV, USA.Three abstracts were presented from Photocure's U.S. Blue Light Cystoscopy with Cysview Registry, a large multicenter bladder cancer patient registry of real-world data, established by Photocure in 2014 and projected to enroll 4,400 patients. In addition, the study protocol of a randomized controlled non-inferiority trial comparing a multidisciplinary approach including PDD-guided primary TURBT to reduce the patients' burden of second resection including a total of 327 patients has been presented. This investigator-initiated trial is supported by Photocure.The abstract sessions on Saturday, April 26:"Upstaging and Risk Migration with BLC for NMIBC: Results from a prospective multicenter registry" by Alireza Ghoreifi, Duke UniversityThe study looked at 2,854 NMIBC* patients from the US Blue Light Cystoscopy with Cysview Registry. A total of 201 (7%) patients had at least one malignant lesion detected exclusively by BLC while having a negative WLC